CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, i...
Phase 3
Louisville, Kentucky, United States and 59 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Louisville, Kentucky, United States and 72 other locations
of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...
Phase 2
Louisville, Kentucky, United States and 51 other locations
drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...
Phase 1, Phase 2
Louisville, Kentucky, United States and 29 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Louisville, Kentucky, United States and 285 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Louisville, Kentucky, United States and 181 other locations
Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...
Phase 3
Louisville, Kentucky, United States and 135 other locations
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple...
Phase 2
Louisville, Kentucky, United States and 11 other locations
find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any sign...
Phase 1, Phase 2
Louisville, Kentucky, United States and 41 other locations
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma...
Phase 2
Louisville, Kentucky, United States and 76 other locations
Clinical trials
Research sites
Resources
Legal